Please assess the completion status of the following clinical trial:

Trial Title: Pivotal Study in VAP Suspected or Confirmed to be Due to Pseudomonas Aeruginosa

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Subject has received mechanical ventilation for at least 48h at the time of the randomisation~* Acute Physiology and Chronic Health Evaluation (APACHE) of 8 to 30, inclusive, within 24h prior to randomization~* Presence of new or progressive infiltrate on chest X-ray~* Presence of clinical criteria consistent with VABP~* High probability of VABP caused by Pseudomonas aeriginosa~Key Exclusion Criteria:~* Known or suspected community-acquired bacterial pneumonia or viral, fungal, or parasitic pneumonia~* Known hypersensitivity or contra-indications to beta-lactam antibiotics, aminoglycosides, quinolones, colistin, or subjects with a clinically significant history of anaphylactic reaction~* Severe liver or renal impairment~* Women who are pregnant or nursing, or who are of chilbearing potential and unwilling to use acceptable method of birth control

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Murepavadin (Type: EXPERIMENTAL): Murepavadin IV + one anti-pseudomonal antibiotic
- Two anti-pseudomonal antibiotics (Type: ACTIVE_COMPARATOR): Association of 2 anti-pseudomonal antibiotics

Based on this trial design, predict the completion outcome and termination type (if applicable).